Rechercher dans ce blog

Monday, February 28, 2022

Pfizer-BioNTech COVID vaccine less effective against infection for kids 5 to 11, study suggests - CBC News

Two doses of the Pfizer-BioNTech COVID-19 vaccine was protective against severe disease in children aged five to 11 during the recent Omicron variant surge, but quickly lost most of its ability to prevent infection in the age group, according to a study by New York State researchers.

The vaccine's efficacy against infection among those children declined to 12 per cent at the end of January from 68 per cent in mid-December compared to kids who did not get vaccinated, according the study, which has not yet been peer reviewed.

For those aged 12 to 17, the vaccine's protection against infection fell to 51 per cent in late January from 66 per cent in mid-December.

"These results highlight the potential need to study alternative vaccine dosing for children and the continued importance layered protections, including mask wearing, to prevent infection and transmission," the researchers said.

The vaccine was around 48 per cent effective in keeping the younger age group out of the hospital, with 73 per cent efficacy against hospitalization among adolescents last month, the data showed.

That was down from effectiveness of 100 per cent and 85 per cent against hospitalization for the two age groups as of mid-December.

Small number of hospitalizations

Dr. Paul Offit, a pediatric infectious disease expert at Children's Hospital of Philadelphia, questioned whether the data were robust enough to say that the vaccine's efficacy had significantly declined, particularly against severe disease.

"It's not surprising that protection against mild illness would wane," Offit said. "We know that Omicron is somewhat immune evasive for protection against mild illness. The goal of the vaccine is to protect against severe illness — to keep children out of the hospital."

Offit said the number of hospitalizations were too few to draw any real conclusions, and that there was little information on why the children were hospitalized. He noted that protection from previous infection among the unvaccinated might also skew the numbers.

"Natural infection can protect against serious illness," he said.

Younger children receive a lower 10-microgram dose of the vaccine than 12- to 17-year-olds, who receive the same 30-microgram dose as adults and are eligible for a third booster shot.

Pfizer said it is studying a three-dose schedule of the vaccine in the pediatric population, noting that studies in adults suggest that "people vaccinated with three doses of a COVID-19 vaccine may have a higher degree of protection."

Adblock test (Why?)


Pfizer-BioNTech COVID vaccine less effective against infection for kids 5 to 11, study suggests - CBC News
Read More

COVID-19 vaccination opportunities: week of February 28, 2022 - Public Health Sudbury & Districts

Public Health Sudbury & Districts is offering several convenient opportunities in the Sudbury & Manitoulin districts this week to help you get your COVID-19 vaccine. Don’t delay. Get your first and second dose as soon as possible and your third dose if you are eligible. A reminder that second and third dose appointments must be booked after you have received your first dose.

Vaccination opportunities for the week of February 28

More opportunities may be added throughout the week. For regular updates, follow us on social media @PublicHealthSD (Facebook, Twitter). Visit us online for up-to-date clinic details, including the clinic times and mRNA vaccine brand that is planned at phsd.ca/COVID-19/vaccine-clinics.

Public Health has redeployed staff to quickly ramp up local capacity and vaccination appointments due to increased eligibility. We appreciate everyone’s patience and understanding while clinic staff work diligently to offer vaccinations. Please be kind, be patient, and be respectful to one another; know that you may wait sometime before being immunized, and that our ability to immunize walk-ins is based upon having sufficient vaccine supplies. We are constantly working to increase our capacity. Be kind and stay safe.

Monday, February 28

Appointment and walk-in clinics

  • Chelmsford Community Centre and Arena, Chelmsford
  • Valley East Public Library, Hanmer

Walk-in only clinic

  • C.R. Judd Public School, Capreol
  • St. Mary Catholic School, Massey

Tuesday, March 1

Appointment and walk-in clinics

  • Carmichael Arena, Greater Sudbury

Walk-in only clinic

  • École Alliance St-Joseph, Chelmsford
  • The Parkside Centre, Greater Sudbury

Walk-in only, mobile bus clinic

  • Laurentian University, outside of the Parker Building, Greater Sudbury

Wednesday, March 2

Appointment and walk-in clinics

  • Southridge Mall, Greater Sudbury

Walk-in only clinic

  • École publique Jeanne-Sauvé, Greater Sudbury
  • Little Current Public School, Little Current

Walk-in only, mobile bus clinic

  • Toe Blake Memorial Arena, Coniston

Thursday, March 3

Appointment only clinic

  • Public Health Sudbury & Districts’ Chapleau office, Chapleau

Appointment and walk-in clinics

  • Carmichael Arena, Greater Sudbury
  • Garson Community Centre and Arena, Garson

Walk-in only, mobile bus clinic

  • Laurentian University, outside of the Parker Building, Greater Sudbury

Friday, March 4

Appointment and walk-in clinics

  • Southridge Mall, Greater Sudbury

Walk-in only clinic

  • Goodlife Fitness, Greater Sudbury

Walk-in only, mobile bus clinic

  • Food Basics, Greater Sudbury

Saturday, March 5

Appointment and walk-in clinics

  • Carmichael Arena, Greater Sudbury

Walk-in only, mobile bus clinic

  • Diggs & Dwellings, Greater Sudbury

Sensory-friendly service

Sensory-friendly is a service for individuals who require accommodations for sensory sensitivities during immunization.

How it works: Sensory-friendly services may include a private immunization station at one of our mass clinics where lights can be dimmed, noise kept to a minimum, and extra time allotted for the appointment.  Alternatively, vaccine-to-vehicle service can be provided within a vehicle at the parking lot of a mass clinic as an alternative for those requiring sensory accommodations.

How to book: Appointments can only be booked by phone through the local call centre at 705.674.2299 (toll-free: 1.800.708.2505). The call centre is open Monday to Friday between 8 a.m. and 6 p.m. and is closed on statutory holidays.  Booking online is not available.

Vaccine-to-vehicle service

Vaccine-to-vehicle is a service available at select mass immunization clinics. This service is available for individuals who are unable to receive their vaccine within a clinic setting for reasons such as sensory sensitivities, decreased mobility, or other health concerns.

How it works: An immunizer will come outside to the parking lot to provide the vaccine to individuals in their vehicle.

How to book: Appointments can only be booked by phone through the local call centre at 705.674.2299 (toll-free: 1.800.708.2505). The call centre is open Monday to Friday between 8 a.m. and 6 p.m. and is closed on statutory holidays.  Booking online is not available.

Please note that during extreme weather or extreme cold that your appointment may be rebooked to ensure everyone’s safety.

Pharmacies and primary care

With many pharmacies and primary care providers providing COVID-19 vaccination, there are even more options available to get your first or second dose locally, every week. Visit covid-19.ontario.ca/vaccine-locations (Government of Ontario) for a list of pharmacies in Ontario offering COVID-19 vaccination and for booking information or contact your primary care provider.

Flu and COVID-19

As we navigate the COVID-19 pandemic, getting your flu shot is also important to help save lives and reduce the burden on our health care system. The influenza and COVID-19 vaccines can be safely administered to individuals 12 years of age and older at the same time. Children 5 to 11 years of age must wait at least 14 days before or after receiving another vaccine prior to receiving the COVID-19 vaccine. The influenza vaccine is readily available at many locations throughout the community, including local pharmacies and health care providers’ offices.

Questions about vaccination

Whether you have questions about getting your first, second, or third dose of vaccine or you have questions about youth vaccination, our clinic immunizers as well as our call centre staff can help answer your questions. Your health care provider is also a trusted source of reliable and credible information. Choosing vaccination is a choice and everyone deserves to have the information they need to be well informed.

Vaccine brands offered and supplies

All Public Health clinics offer one of two mRNA vaccine brands—either Moderna Spikevax or the pediatric and adult dose of Pfizer-BioNTech Comirnaty.  As the province now has confirmed stable supply of the adult Pfizer-BioNTech Comirnaty vaccine, the requirement to prioritize Pfizer-BioNTech for the 12 to 29 age group is no longer in effect. Moving forward and as supply permits, Public Health Sudbury & Districts will ensure both vaccine products are available in our mass immunization clinics while continuing to first offer Moderna Spikevax to those 30 years of age and older. A reminder that for those 30 and older, the adult dose of Pfizer-BioNTech Comirnaty and Moderna Spikevax vaccines can be safely interchanged. Based on vaccine supplies, the vaccine brand planned for use at any clinic is subject to change, possibly with limited notice. We encourage you to ask our immunizers for more information to help you make an informed decision and feel comfortable about getting either vaccine brand. To learn which mRNA vaccine brands are planned for our clinics, visit phsd.ca/COVID-19/vaccine-clinics.

Eligibility for COVID-19 vaccines

First dose eligibility

  • Individuals five years of age and older can receive a first dose of COVID-19 vaccine.
    • Pfizer-BioNTech Comirnaty pediatric dose (10 micrograms) is approved for children 5 years of age and older. Children 5 to 11 years of age must wait at least 14 days before or after receiving another vaccine prior to receiving the COVID-19 vaccine.
    • Pfizer-BioNTech Comirnaty (30 micrograms) is approved for youth who are 12 years and older.
    • The Pfizer-BioNTech Comirnaty is preferentially recommended for individuals aged 18 to 29 years old and the only approved vaccine for youth aged 12 to 17.
    • Everyone aged 29 and over can receive either Pfizer-BioNTech Comirnaty or Moderna Spikevax. These 2 mRNA vaccines can be safely interchanged.

Second dose eligibility

  • Children aged 5 to 11 who received their first pediatric dose of Pfizer-BioNTech more than 8 weeks ago.
  • Youth aged 12 years and older who received their first dose of Pfizer-BioNTech Comirnaty vaccine more than 56 days (8 weeks) ago.
  • Anyone who received their first dose of Moderna Spikevax vaccine more than 56 days (8 weeks) ago.
  • People who received AstraZeneca Vaxzevria 56 days ago (at least 8 weeks) and who would like to get an mRNA vaccine.
  • The National Advisory Committee on Immunization (NACI) and Ontario Ministry of Health recommend an optimal interval of 8 weeks (56 days) between first and second doses of a two-dose COVID-19 vaccine series (Pfizer-BioNTech Comirnaty or Moderna Spikevax). According to NACI, there is emerging evidence that longer intervals between the first and second doses of COVID-19 vaccines result in more robust and durable immune response and higher vaccine effectiveness. Public Health will administer second doses 8 weeks (56 days) following administration of a first dose, with limited exceptions.

Third dose eligibility

The Government of Ontario recommends a third dose of a COVID-19 vaccine as part of a primary vaccine series (meaning 3 doses are needed for full immunity) for the following individuals:

Booster dose eligibility

The Government of Ontario recommends a booster dose of a COVID-19 vaccine to restore protection that may have decreased over time to a level for the following individuals:

  • Individuals 18 years of age and older who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Individuals 12 to 17 years of age who received their second dose of COVID-19 vaccine at least six months (168 days) or 3 months (84 days) with informed consent.
  • First Nations, Inuit, and Métis adults 18 years of age and older including non-Indigenous household members, who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Eligible health care workers 18 years of age and older who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks) (see details at phsd.ca/COVID-19/vaccine-clinics).
  • Individuals who received 2 doses of the AstraZeneca/COVISHIELD COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Individuals who received 1 dose of the Janssen/ Johnson & Johnson COVID-19 vaccine at least 3 months ago (84 days, 12 weeks).
  • Vulnerable older adults in congregate settings who received their second dose of COVID-19 vaccine at least 3 months ago (84 days, 12 weeks) (see details at phsd.ca/COVID-19/vaccine-clinics).
  • Moderately to severely immunocompromised individuals who are eligible for a three dose primary series may receive a booster dose (a fourth dose) 6 month (168 days, 24 weeks) after their third dose.

In addition, as of 8 a.m. on Friday, February 18, 2022, Ontario is expanding booster dose eligibility to youth aged 12 to 17.

For detailed information on eligibility for first, second, and third doses, visit phsd.ca/COVID-19/vaccine-clinics.

Second and third dose appointments

Anyone eligible for a second or third dose can book an appointment as soon as they are eligible. To book online, visit covid-19.ontario.ca/book-vaccine or call 705.674.2299 (toll-free: 1.800.708.2505), between 8 a.m. and 6 p.m., Monday to Friday. For a list of scheduled clinics, visit phsd.ca/COVID-19/vaccine-clinics.

Preparing for a COVID-19 vaccination appointment

All vaccination clinics have COVID-safety measures in place. You must not attend a clinic if you have any symptoms of COVID-19 or if you are in isolation due to a COVID-19 exposure.

  • Bring your health card. If you do not have a health card or your health card is expired, bring another form of government-issued photo identification such as a driver’s license, passport, Status card, or birth certificate.
  • Eat and drink something before you arrive at your appointment to prevent feeling faint or dizzy while being vaccinated.
  • Do not show up until 5 minutes before your scheduled appointment.
  • When possible, please limit the number of support people attending a vaccination clinic to one person.
  • Dress for the weather, you may have to wait in line if you plan on attending a walk-in clinic.
  • Wear a top that allows for easy access to the upper arm such as a loose-fitting top or a t-shirt.
  • Wear a medical mask that covers your nose, mouth, and chin. If you do not have a medical mask, pediatric and adult medical masks will be available at the entrance to the clinic.
  • If you have symptoms of COVID-19, do not attend the clinic.

For more information or if you have questions, please talk to trusted sources such as Public Health immunizers at COVID-19 vaccine clinics, health care providers, and pharmacists, visit phsd.ca/COVID-19 or call Public Health Sudbury & Districts at 705.522.9200 (toll-free 1.866.522.9200).

Adblock test (Why?)


COVID-19 vaccination opportunities: week of February 28, 2022 - Public Health Sudbury & Districts
Read More

Widow sues Northern Health after death of husband, claims he was misdiagnosed three times at FSJ Hospital - Energeticcity.ca

The CBC article says Stewart’s claims have not been proven, and the physicians and Northern Health have yet to file a response in court.

Stewart told the CBC that Wakely initially visited the hospital with “a severe sore throat” prior to midnight on February 24th, 2020, and was treated with Tylenol and fluids for suspected tonsillitis, before being sent home.

According to the lawsuit filed last Tuesday in B.C. Supreme Court, doctors didn’t swab Wakely’s throat or run a rapid test for strep. He was then transferred back to hospital by paramedics on February 26th with back spasms.

“He had taken numerous medications that day, including 12 tablets of Robaxacet, seven tablets of Advil, seven tablets of Motrin, and one tablet of Tylenol with codeine but still rated his pain as 10/10,” the claim read.

He was diagnosed with muscle spasms and sacroiliitis, given Tylenol 3s and sent home again.

He was back in hospital on February 27th with “pain, swelling and loss of sensation” radiating up his arm from his right hand and wrist, according to the lawsuit.

Wakely was diagnosed with hand-arm vibration syndrome, due to his work as a welder, and was sent home again, this time with Advil and the advice to avoid vibrating tools.

The lawsuit claims the doctors on his last two visits failed to order lab tests or bloodwork and didn’t reference his previous visits.

A CBC reporter reached out to a Northern Health spokesperson who said they couldn’t comment.

“At this time, Northern Health has not been served regarding this statement of claim. NH cannot comment further, as the litigation process is underway,” said an email to CBC.

Stewart travelled a 2,000-kilometre round trip to bring him home to the Okanagan after the third hospital visit, and Wakely was taken to Kelowna General Hospital the day after they got home, the claim said.

Lab work confirmed a strep A infection, according to the lawsuit. The bacteria can cause a range of diseases, ranging from minor cases of strep throat to life-threatening illnesses, including Necrotizing fasciitis.

The rare disease bacterial infection spreads quickly in the body and can cause death, according to the U.S. Centers for Disease Control and Prevention. Necrotizing fasciitis looks similar to other infections in its early stages often making it hard to diagnose, the centre said.

Quick treatment of the illness is important, and up to one and three people die from the infection, according to the CDC.

Wakely underwent surgery in an attempt to remove dead tissue, but the claim said he died just before 1:30 a.m. on March 2nd.

Stewart is suing four physicians and Northern Health for negligence, seeking compensation under the Family Compensation Act on behalf of herself, her son and her in-laws.

With files from Rhianna Schmunk, CBC

Adblock test (Why?)


Widow sues Northern Health after death of husband, claims he was misdiagnosed three times at FSJ Hospital - Energeticcity.ca
Read More

Pfizer vaccine significantly less effective in kids 5-11: study - CW33 NewsFix

[unable to retrieve full-text content]

  1. Pfizer vaccine significantly less effective in kids 5-11: study  CW33 NewsFix
  2. Pfizer-BioNTech COVID vaccine less effective against infection for kids 5 to 11, study suggests  CBC News
  3. Pfizer vaccine significantly less effective in children ages five to 11, study shows  The Guardian
  4. Pfizer Covid vaccine was just 12% effective against omicron in kids 5 to 11, study finds  CNBC
  5. View Full coverage on Google News

Pfizer vaccine significantly less effective in kids 5-11: study - CW33 NewsFix
Read More

Sunday, February 27, 2022

Savvy Senior: Can COVID-19 cause shingles? | Qa | richmond.com - Richmond.com

QUESTION: How effective is the shingles vaccine and what is the CDC recommendation for getting it? My older brother and sister, both in their 50s, got COVID-19 a few months back followed by shingles. Do you know if there is a connection between these viruses, and would the shingles vaccine have protected them?

ANSWER: Many health care professionals across the country have been urging their older patients to get the shingles vaccine (in addition to the COVID-19 vaccinations) during the pandemic because getting COVID-19 can increase your chances of developing shingles. And the more severe case of COVID you get, the greater your risk for shingles.

The reason for this is because when you contract COVID-19 your immune system becomes compromised fighting off the virus, which gives shingles — a virus that already exists in your body if you’ve had chickenpox — a chance to reactivate.

Here’s what you should know about shingles, the shingles vaccine and the Centers for Disease Control and Prevention recommendations.

People are also reading…

What is shingles?

Shingles, also known as herpes zoster, is a burning, blistering skin rash that affects around 1 million Americans each year. The same virus that causes chickenpox causes shingles. What happens is the chickenpox virus that most people get as kids never leaves the body. It hides in the nerve cells near the spinal cord and, for some people, emerges later in the form of shingles.

In the United States, about 1 out of every 3 people will develop shingles during their lifetime. While anyone who’s had chickenpox can get shingles, it most commonly occurs in people over age 50, along with people who have weakened immune systems. But you can’t catch shingles from someone else.

Early signs of the disease include pain, itching or tingling before a blistering rash appears several days later, and can last up to four weeks. The rash typically occurs on one side of the body, often as a band of blisters that extends from the middle of your back around to the breastbone. It can also appear above an eye or on the side of the face or neck.

In addition to the rash, about 20% to 25% of those who get shingles go on to develop severe nerve pain (postherpetic neuralgia, or PHN) that can last for months or even years. And, in rare cases, shingles can also cause strokes, encephalitis, spinal cord damage and vision loss.

Shingles vaccine

The vaccine for shingles called Shingrix (see Shingrix.com) provides much better protection than the old shingles vaccine, Zostavax.

Manufactured by GlaxoSmithKline, Shingrix is 97% effective in preventing shingles in people 50 to 69 years old, and 91% effective in those 70 and older.

Shingrix also does a terrific job of preventing nerve pain that continues after a shingles rash has cleared — about 90% effective.

Because of this protection, the CDC recommends that everyone age 50 and older, receive the Shingrix vaccine, which is given in two doses, separated by two to six months.

Even if you’ve already had shingles, you still need these vaccinations because reoccurring cases are possible. The CDC also recommends that anyone previously vaccinated with Zostavax be revaccinated with Shingrix.

You should also know that Shingrix can cause some adverse side effects for some people, including muscle pain, fatigue, headache, fever and upset stomach.

Shingrix — which averages around $205 for both doses — is covered by most private health insurance plans, including Medicare Part D prescription drug plans, but there may be a cost to you depending on your plan. Contact your insurer to find out.

Jim Miller is editor of the Savvy Senior. Send your senior questions to Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit www.savvysenior.org.

Adblock test (Why?)


Savvy Senior: Can COVID-19 cause shingles? | Qa | richmond.com - Richmond.com
Read More

Mental wellness: UBC study examines impact of daily experiences on mental health - Richmond News

A UBC researcher is hoping to learn more about how daily experiences affect mental well-being.

Nancy Sin, of UBC’s UPLIFT Health Lab and assistant professor in the Department of Psychology, said the goal of the study is to understand how people are coping with daily life both during the pandemic and in the “transition phase…back to a more normal kind of day-to-day life.”

As part of the study, participants — who must be over the age of 25 — must fill out surveys throughout the day for two weeks, wear a sleep watch and physical activity monitor and collect saliva samples so Sin and her team can look at their stress hormones.

“I’m really interested in their positive experiences. We do ask about their emotions, about the kinds of stressful events and their social interactions. And embedded within our questions about social interactions, we do ask about whether people were treated unfairly or had experienced any discrimination that day,” said Sin.

“We’re hoping that with that information, we can understand these variations in how people are responding to stress and also what kinds of experiences in daily life allow people to cope better with stress.”

She said the study was first launched before the pandemic, but the pandemic then forced it to then be put on hold until last year.

So far, about 200 participants from around B.C. have enrolled, said Sin, who is now hoping to get more people from the local community involved – particularly individuals who identify as part of a minority group.

“This is really important for us. We want to make sure that we have a diverse sample and that the data that we are collecting (reflects) the experiences of people from all walks of life.”

Sin said the data collected in the study could help inform programs to boost emotional well-being as well as policy changes to better direct resources.

For example, earlier on in the pandemic, Sin and her team researched age differences in emotional wellbeing.

“Based on that work, it really seems that there’s an opportunity for older adults and young adults to link up, for example, in intergenerational volunteering programs,” she said. “That can reduce loneliness and facilitate more social wellbeing and more social interactions between different generations.”

When it comes to sleep, Sin said some policy changes that could be looked at include changes in the workplaces or school start times, or how families can help set good sleep behaviours.

Anyone interested in participating in the Daily Experiences and Health Study can learn more online at https://blogs.ubc.ca/dailyhealth/.

Adblock test (Why?)


Mental wellness: UBC study examines impact of daily experiences on mental health - Richmond News
Read More

Saturday, February 26, 2022

Hoarding: people with ADHD are more likely to have problems - new research - ThePrint

London, Feb 26 (The Conversation) Many of us may find we have acquired too many possessions that clutter our living spaces, but refuse to part with things “in case we might need them”.

Although having too much stuff is something many of us can relate to, for some people, a persistent difficulty parting with possessions can become a problem: hoarding. When these tendencies significantly impair somebody’s quality of life, this leads to a condition called hoarding disorder.

Curiously, understanding how hoarding manifests and how it relates to other difficulties in everyday life has not received much attention until recently. Only in 2013 was hoarding disorder officially recognised in the DSM-5 (the American Psychiatric Association’s manual for assessing and diagnosing mental health conditions), and its key characteristics agreed upon.

In a recent study, we found people with attention deficit/hyperactivity disorder (ADHD) have a significantly higher frequency of hoarding symptoms compared to the general population. This indicates that hoarding should be routinely assessed in those with ADHD.

Hoarding disorder is characterised by persistent difficulties discarding items, regardless of their actual value. This results in excessive accumulation of possessions that clutter living areas and compromise their intended use. Hoarding disorder leads to major distress and problems in socialising, work and other areas of daily functioning.

Anecdotally we know participants in hoarding research often report problems with attention, with many believing that they should have received a diagnosis of ADHD. Indeed, evidence does indicate that people with hoarding disorder experience greater problems with attention compared to others.

ADHD is a neurodevelopmental condition, with one of its key characteristics being problems with attention. “Inattention” encompasses issues with concentrating, but also considerable difficulties with organisation, forgetfulness, procrastination and being easily distracted to a degree that impairs everyday functioning.

If there is a link between hoarding and inattention, then what about people with ADHD? Do they have more hoarding problems than most? Our study We asked all patients in an adult ADHD clinic in the UK to complete a series of questionnaires about their traits and behaviours including hoarding. We had 88 people, one-third of the patients, take part. A control group with similar age, gender and education characteristics who did not have ADHD answered the same questions.

Using three different questionnaires, we applied thresholds previously established by hoarding researchers and clinicians to indicate hoarding disorder. Some 20% of participants with ADHD reported clinically significant hoarding symptoms, versus 2% in the comparison group (close to the 2.5% prevalence of hoarding disorder in the population).

Hoarding was roughly as common across both genders, with patients who exhibited hoarding symptoms aged on average in their 30s. Clinically significant hoarding in ADHD patients was associated with poorer quality of life and higher depression and anxiety.

People with ADHD who scored below the threshold for hoarding disorder still reported considerably greater issues with hoarding compared to the control group. Further, those with more severe attention problems were more likely to report problems with hoarding.

Even if not suffering from either ADHD or hoarding disorder, many people will relate to the difficulties characteristic of these conditions, demonstrating that symptoms exist along a continuum in the population. We therefore reran the study online in 220 UK participants, finding this time that 3.6% scored above the threshold, and that there was again a strong link between inattention and hoarding.

The findings from our study, which we understand is the first to examine hoarding in adult ADHD patients, suggest that people with ADHD should be routinely assessed for hoarding symptoms – particularly given the limited awareness around any impairments associated with hoarding. While patients did not spontaneously raise hoarding-related issues in the clinic, they did endorse them once explicitly raised in our study.

Research gaps A limitation of our study is that hoarding symptoms were investigated with self-reported questionnaires. Future studies should replicate the findings with trained clinical staff assessing hoarding through interviews. Future research should also investigate why this association between ADHD and hoarding disorder exists.

More generally, one challenge to understanding hoarding and providing effective treatment is that many of those who suffer from hoarding disorder have limited insight. This means they don’t necessarily recognise or accept that they are suffering from a mental health condition, or that they have a problem at all.

Research on hoarding disorder has tended to focus on people who do come forward or those noticed by health and social care systems. Time and again studies describe samples of predominantly female participants in their late 50s. But these participants tell of severe hoarding beginning much earlier in life, often by one’s 20s.

In addition, indirect evidence from demographic studies suggests that hoarding is evenly split across genders.

The evidence from our study indicates that our understanding of hoarding may be enriched by targeting these younger people with ADHD and hoarding to get a fuller understanding of their symptoms. This could ultimately support more effective interventions and treatments in both ADHD and hoarding disorder, and help illuminate the link between the two. (The Conversation) SCY SCY

This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

Adblock test (Why?)


Hoarding: people with ADHD are more likely to have problems - new research - ThePrint
Read More

N.W.T. health officials believe tainted drugs killed two people - CBC.ca

Two people who recently died in a southern N.W.T. community may have overdosed on opioid-tainted cocaine, according to the territory's Coroner's Office.

On Thursday evening, the Office of the Chief Public Health Officer issued a health alert about the deaths. It said all communities in the N.W.T. are at risk because "illicit drug supplies can involve every N.W.T. community."

The alert stated the Coroner's Office believes the deaths were due to overdoses, "potentially from cocaine mixed with other substances."

"With Canada experiencing a high number of opioid deaths, the concern is the deaths are due to opioid adulterants," it stated.

The Office of the Chief Public Health Officer said since illegal drugs can involve every community, all are at risk of receiving tainted drug supplies.

"Mixing substances increases the risk of overdose," the alert stated.

Canada has a law that means people who are overdosing, or who are witnessing an overdose, can't be charged for possessing drugs. The alert stated that's to encourage people to call an ambulance or their local health centre.

All health centres, pharmacies and hospitals in the territory also have naloxone kits available, which can stop opioid overdoses.

Adblock test (Why?)


N.W.T. health officials believe tainted drugs killed two people - CBC.ca
Read More

Friday, February 25, 2022

Even more infectious sub-variant of Omicron is now DOMINANT in England - Daily Mail

Even more infectious sub-variant of Omicron is now DOMINANT in England but health chiefs insist BA.2 strain is no more lethal - and they reveal they've now also spotted 32 case of 'Deltacron'

  • UKHSA scientists say Omicron sub-type BA.2 now makes up 52 per cent of cases
  • But there is no evidence it leads to more admissions or is better at dodging jabs
  • Scientists also warned 32 cases of 'Deltacron' have been detected in the UK 

An even more infectious version of Omicron is now dominant in England, health chiefs revealed today.

BA.2 was behind 52 per cent of all Covid infections in the seven days to February 20, up from 19 per cent a fortnight ago, the UK Health Security Agency found.

The sub-variant has completed its rapid rise to dominance just a month after it was first spotted in the UK.

But the scientific community has said there is no reason to panic, with the variant already almost every case in Denmark but leading to no effect on  hospitalisations or deaths.

The Government there deemed the strain such a non-threat that it has ended virtually all Covid restrictions — like England did this week.

There is so far no evidence BA.2 is more severe or better at evading vaccine-induced immunity than the original Omicron.

And Professor Paul Hunter, an infectious diseases expert at the University of East Anglia, told MailOnline it was unlikely to even cause cases — which have been falling for weeks — to pick back up. 

Writing in today's report, the UKHSA also revealed 32 cases of 'Deltacron' had now been spotted in England.

The hybrid of Omicron and Delta emerged January 7, in a person who had both variants at the same time.

It has triggered just two infections in the past week.

Britain's Covid cases have fallen consistently for the last three weeks, while deaths and hospitalisations are already trending downwards. 

The above graph shows that BA.2 - a sub-variant of Omicron - is now behind 52.3 per cent of all Covid cases in England. It is now dominant over old Omicron

The above graph shows that BA.2 - a sub-variant of Omicron - is now behind 52.3 per cent of all Covid cases in England. It is now dominant over old Omicron

The weekly report showed BA.2 was behind the highest proportion of cases in London (62.9 per cent of Covid cases). It was also dominant in the South East (57.1 per cent), East of England (52.6 per cent), North West (51.1 per cent) and West Midlands (50 per cent)

The weekly report showed BA.2 was behind the highest proportion of cases in London (62.9 per cent of Covid cases). It was also dominant in the South East (57.1 per cent), East of England (52.6 per cent), North West (51.1 per cent) and West Midlands (50 per cent)

Government scientists also said they had detected 32 cases of 'Deltacron'. But the hybrid appears to have fizzled out rather than taking off in a promising sign

Government scientists also said they had detected 32 cases of 'Deltacron'. But the hybrid appears to have fizzled out rather than taking off in a promising sign

BA.2 carries many of the same mutations as Omicron alongside many new ones that make it more transmissible.

But, unlike its parent, it carries an S-gene meaning it can be easily distinguished from the original Omicron without the need for genomic sequencing.

UK's £5.6bn Covid jabs rollout was 'good value' for money 

Britain's Covid vaccination drive was good value for money, No10's public spending watchdog has claimed.

The National Audit Office heaped further praise on the £5.6bn jabs rollout – adding that far fewer doses were wasted than predicted.

It claimed securing a supply of vaccines early on in the pandemic was 'crucial' to its success and this helped to 'save lives and reduce serious illness and hospitalisation'.

The independent watchdog warned there were still risks ahead for the programme, however, including staff burnout.

In a report released today, covering a period up to the end of October 2021, the NAO said wastage of about 4.7 million doses – 4 per cent of the total – had been 'much lower than the programme initially assumed'.

UKHSA scientists used this to estimate BA.2's prevalence.

Delta also has an S-gene, but the variant has been completely eradicated in the UK by the two much more virulent strains.

London had the highest share of BA.2 (63 per cent of Covid cases), followed by the South East (57 per cent), East of England (53 per cent), North West (51 per cent) and West Midlands (50 per cent).

The regions where it was not dominant were the East Midlands (49 per cent), Yorkshire and the Humber (43 per cent), North East (33 per cent) and South West (33 per cent). 

Professor Hunter said: 'Ultimately, we could have done without BA.2, but it will not make too much of an impact.'

He added: 'I don't think BA.2 is going to undermine the current drop in cases.

'The consensus opinion of epidemiologists that I've listened to is that it is probably not going to be something that will undermine our position.' 

A fortnight ago the UKHSA revealed it had spotted the UK's first case of the so-called Deltacron in England.

The agency said they were keeping tabs on the hybrid, but that it was not concerning because there was no noticeable uptick in cases.

Scientists also called for calm, saying it 'shouldn't pose too much of a threat' because the UK has such high levels of immunity against both Omicron and Delta strains.

Despite the rise in BA.2, Government dashboard data shows that Britain's cases, hospitalisations and deaths are all trending downwards even as the more infectious version of Omicron became dominant.

It has given Boris Johnson the confidence to lift the final Covid restrictions, with self-isolation coming to an end yesterday for the first time in almost two years.

Free Covid tests are also set to end from the start of April, ministers have announced, in a drive to save £2billion a month.

Mr Johnson said he could lift the final Covid restrictions because of widespread immunity and the mildness of Omicron.

But he warned this was not victory over the virus, adding that it was not yet 'going away'. 

SAGE scientists have warned the mildness of Omicron may be a 'chance event', and say it is a 'common misconception' that viruses become weaker overtime.

But other scientists argue that high levels of immunity in the country mean it will not experience a Covid wave like in March 2020 again. 

Adblock test (Why?)


Even more infectious sub-variant of Omicron is now DOMINANT in England - Daily Mail
Read More

Skipping Second Dose of mRNA COVID-19 Vaccine May Limit Myocarditis in Adolescents - TCTMD

A strategy of spreading out the two doses, instead of forgoing the second, might be a better option, one expert indicates.

Moving to just one dose of an mRNA-based COVID-19 vaccine for adolescents appears to limit associated rare cases of myocarditis, according to a study out of Hong Kong.

Of 43 vaccine-related myocarditis cases identified, none occurred after a single-dose policy was implemented, lead author Xue Li, PhD (Li Ka Shing Faculty of Medicine, University of Hong Kong), and colleagues report in a JAMA Pediatrics research letter.

They estimate that about nine myocarditis cases were prevented with the change, but acknowledge that the analysis is limited by the small sample size in the post-implementation population. They also point out that study covered a period of time before the Omicron variant started circulating and when there was little local transmission of SARS-CoV-2 thanks to strict nonpharmaceutical control measures and an “extremely low” risk of COVID-19-related death or complications among adolescents.

“Vaccination policy for adolescents should consider the trade-off between risks and benefits,” Li et al say. “In countries with large outbreaks and to [prevent] local transmission, the risk-benefit assessment would favor a two-dose regimen because the single-dose regimen provides suboptimal protection from severe outcomes associated with COVID-19. However, in settings with no evident local transmission and stringent infection control policies, single-dose mRNA vaccination might be a viable option for offering protection to adolescents from severe outcomes associated with COVID-19.”

Shortly after countries started rolling out COVID-19 vaccines in early 2021, reports began to emerge about cases of myocarditis developing in the days following the shots, particularly the mRNA-based vaccines from Pfizer/BioNTech and Moderna. As more data were collected, it became clear that such cases—though rare—were concentrated in younger males and generally had relatively benign clinical consequences. Still, because of the higher rates seen in younger age groups, some countries—including Norway, the United Kingdom, and Taiwan—suspended the second dose of the primary series for adolescents. In Hong Kong, it was recommended that those ages 12 to 17 should receive only one dose of Pfizer/BioNTech vaccine, starting September 15, 2021.

Li et al examined the temporal relationship between this policy shift and cases of myocarditis reported after receipt of the Pfizer/BioNTech vaccine by linking vaccination records and electronic health records for adolescents ages 12 to 17 who received at least one dose between March 10, 2021 (when the Hong Kong vaccination program began) and October 18, 2021, excluding individuals with a prior history of myocarditis. The analysis included 224,560 first doses and 162,518 second doses.

Overall, 43 adolescents (mean age 14.86 years; 88% male) had a myocarditis-related hospitalization after receipt of the vaccine; 84% occurred after the second dose. The incidence rates per 100,000 people were 3.12 and 22.15 after the first and second doses, respectively, with corresponding numbers needed to harm of 32,051 and 4,515. All 43 myocarditis cases occurred among the 202,315 adolescents vaccinated before the single-dose policy change, with none among the 22,245 who received shots after that point.

Refining the Benefit-Risk Balance

Though Hong Kong went with the single-dose approach, there are other potential ways to mitigate the already low risk of myocarditis without compromising on efficacy against COVID-19 in adolescents, and Li et al highlight a couple: use of a lower dosage for the two shots in the primary series or an extended interval between the doses.

The US Centers for Disease Control and Prevention (CDC) has warmed to the second option, stating in guidance updated earlier this week that “an 8-week interval may be optimal for some people ages 12 years and older, especially for males ages 12 to 39 years.” The 3- to 4-week interval that has been used for the mRNA-based vaccines remains recommended for “people who are moderately or severely immunocompromised; adults ages 65 years and older; and others who need rapid protection due to increased concern about community transmission or risk of severe disease.”

We’ve seen enough COVID and we’ve had enough tragedy already that we have to continue to be vigilant and try to keep ourselves as vaccinated as possible. Elizabeth Schlaudecker

Commenting for TCTMD, Elizabeth Schlaudecker, MD (Cincinnati Children’s Hospital Medical Center, OH), was supportive of the change for the younger age groups, indicating that a changing pandemic situation allows for more-tailored recommendations to better balance risks and benefits.

“When we were first vaccinating a year ago or more, we were trying to prevent as many deaths as possible as quickly as possible. We were trying to get the pandemic under control and . . . we wanted to get as many people in the population vaccinated as quickly and safely as possible,” she said. “But now it’s sort of a different strategy. We’re trying to look ahead and think: how can we protect people for longer periods of time, so we don’t see a surge in COVID as time goes by?”

Accumulating data, as reported by the CDC, support both the safety and effectiveness of spreading out the two doses for longer intervals.

“The advantage of this spacing out by 8 weeks or more is that we are actually likely getting the same protection but we’re getting it for longer,” Schlaudecker said. “We are seeing a big decrease in infections, [so] we really have that luxury of being able to make sure that we’re [administering vaccines] really safely and preventing myocarditis by spacing it, and hopefully getting a more long-lasting immune response, which is great.”

As for whether a single-dose strategy—like that used in Hong Kong—could be useful in the US, Schlaudecker was skeptical. “We’re very optimistic that numbers are down, and everyone is feeling very encouraged by that, but I don’t think that this is the end of COVID forever,” she said. “I think we will continue to see possibly new variants that emerge, and some of them will be with us for a while, so if that’s the case then I think . . . the risk of just partially vaccinating our population is greater than the risk of deciding that it would be better to get two doses. I’m on the side that I still think that we’ve seen enough COVID and we’ve had enough tragedy already that we have to continue to be vigilant and try to keep ourselves as vaccinated as possible.”

Adblock test (Why?)


Skipping Second Dose of mRNA COVID-19 Vaccine May Limit Myocarditis in Adolescents - TCTMD
Read More

Thursday, February 24, 2022

COVID-19 treatment outpatient virtual service launches | Columbia Valley, Cranbrook, East Kootenay, Elk Valley, Kimberley, Ktunaxa Nation - E-Know.ca

Posted: February 24, 2022

COVID-19 treatment outpatient virtual service launches

A new online assessment tool and virtual service has launched for people to see if they could receive and benefit from COVID-19 anti-viral treatments.

Two therapeutic treatments for COVID-19 are approved for people with confirmed cases of COVID-19 who are at high risk and who are not in hospital: Sotrovimab, which must be given through an infusion and requires a visit to a clinic or hospital; and Paxlovid, which is a course of anti-viral pills that can be taken at home, the Ministry of Health reported Feb. 23.

These treatments are used to prevent severe illness in people who are at higher risk from COVID-19 and need to be started within five days of developing symptoms to be most effective. These treatments must be prescribed by a health-care provider who helps to determine the risk and benefit for individuals, the ministry said.

These treatments are available to:

* those who are clinically extremely vulnerable;

* those who are over 60, not fully vaccinated and have one or more chronic conditions; and

* those who are over 60, not fully vaccinated and are Indigenous.

As part of the new virtual service, British Columbians can find out if these treatments are right for them by following the four-step process available online, starting with the online self-assessment. A physician and pharmacist team will decide as part of the four-step process if treatment is safe and appropriate.

Paxlovid and Sotrovimab treatments are not suitable for everyone and must be prescribed by a health-care provider who can assess interactions with other conditions or medications. Patients may not be able to receive treatment if they are already taking some other medications or herbal supplements, the Health Ministry noted.

“These treatments are not a substitution for vaccines and vaccination is strongly recommended as the most effective way to prevent serious illness.”

Find out if treatments are available to you: gov.bc.ca/covidtreatments

BC Government image

e-KNOW


Article Share

Adblock test (Why?)


COVID-19 treatment outpatient virtual service launches | Columbia Valley, Cranbrook, East Kootenay, Elk Valley, Kimberley, Ktunaxa Nation - E-Know.ca
Read More

Could more nature and less air pollution prevent ADHD? - Vancouver Is Awesome

The less air pollution and more green space a child is exposed to, the less likely they are to develop attention-deficit hyperactivity disorder (ADHD), a sweeping Metro Vancouver-wide study has found. 

The pathbreaking research, published in the journal Environment International, followed a cohort of nearly 30,000 children born in 2000 and 2001. 

Tracing a three-year exposure period, researchers from the University of British Columbia analyzed the combined impacts of satellite-measured green space, noise and concentrations of fine particulate matter smaller than 2.5 micrometres (PM 2.5) on the development of ADHD. Seven years after the exposure period, over 1,200 ADHD cases were diagnosed.

Noise was found to have no effect. But lower the amount of green space or increase the levels of air pollution, and the twin effects can heighten the risk of ADHD by up to 62 per cent, found researchers. The result: "children living in greener neighbourhoods with low air pollution had substantially lower risk of ADHD compared to those with higher air pollution and lower green space exposure," concluded the study.

“I was surprised that we saw this much of a difference,” said Michael Brauer, a co-author on the study and a researcher examining the built environment and human health at UBC’s School of Population and Public Health. 

“Given that there's not a lot of things about ADHD that we can change at a societal level, it is a pretty big effect.”

PM2.5 is the main constituent of wildfire smoke, something only expected to worsen in the coming decades. Outside of the fire season, Metro Vancouver says it's also produced through the burning of fossil fuels in everything from transportation, industry and agriculture. It has been considered a carcinogen since 2013. Across the world, the World Health Organization estimates almost 80 per cent of the deaths related to PM2.5 could be avoided if its guidelines were followed. 

Not all air pollutants were correlated with an increased risk of developing ADHD. Nitrogen dioxide — which together with PM 2.5 and ground-level ozone contributes to over 15,000 annual deaths across Canada and 1,900 in B.C. — was not found to be connected with the development of ADHD.

Brauer says the biggest two sources of air pollution driving the variation in Metro Vancouver were traffic and space heating, including wood-burning and natural gas fireplaces, and gas boilers. 

Closer to the coast and at higher elevations, pollution levels tended to be lower due to ocean breezes and the tendency of pollution to settle in low-lying areas. The worst-hit areas tended to be near major traffic arteries, along highways, major truck routes and the region’s ports.  

A neurodevelopmental disorder, ADHD is thought to affect five to 10 per cent of children and adolescents. Throughout a person's life, it can affect their academic performance and their ability to socialize and work.

As the researchers put it, ADHD has "considerable impacts on individual wellbeing, health care, and the economy." 

The study is part of a wider attempt to understand the environmental health hazards from air pollution and how green spaces can dampen their impacts. 

In October 2021, another Metro Vancouver-wide study from several of the same UBC researchers concluded living near green spaces improves a children's chances of hitting key developmental milestones, including emotional maturity, language skills and even general knowledge. 

Living near green spaces, found the 2021 study, could improve childhood development, partly by reducing the negative effects of air and noise pollution — both have been found to increase stress, sleep disturbances and central nervous system damage in children.

The latest round of research adds to a growing body of evidence of the benefits of green space on human health.

In other parts of the world, past research has found that access to green space can promote a huge range of positive health outcomes for all ages, from increased physical activity and social cohesion to reduced cardiovascular disease and dementia rates. Others have found similar benefits when people regularly expose themselves to bodies of water, known by some as "blue space."

Increased density of trees can also create a buffer for extreme heat and, in the winter, act as a thermal blanket that will reduce heating bills should a deep freeze set in. But how green spaces are distributed across the Metro area can reveal some huge inequalities.

Of the nearly 600 British Columbians who died from extreme temperatures during late June's heatwave, more were killed in low-income areas, where people lived alone and with little green space. On Vancouver's Downtown Eastside, Canada's poorest neighbourhood, hospitalizations tripled, with more people admitted to emergency rooms due to heat than anywhere else in the city.

Scientists know how trees protect us from heat. But how more access to green space makes people healthier over the long term is unclear. 

"Instead of saying green is good, we're providing more concrete pathways," Ingrid Jarvis told Glacier Media last fall.

At the time, Jarvis said the research shows that everyday "micro-contacts" with nature can positively affect a child's long-term physical and mental health. 

“This is one more thing,” added Brauer, referring to the group's latest study. “There’s not a lot known about factors that you can modify. So what we tend to do when kids are diagnosed with ADHD is put them on medication.”

“We could be raising healthier kids.”

Ultimately, their findings have big repercussions for how planners design neighbourhoods in a region expected to add another million people to its population by 2040.

In the past, the group of UBC researchers have sent findings to Metro Vancouver, where it was distributed to all 21 jurisdictions and various committees. 

Adblock test (Why?)


Could more nature and less air pollution prevent ADHD? - Vancouver Is Awesome
Read More

Could more nature and less air pollution prevent ADHD? - Powell River Peak

The less air pollution and more green space a child is exposed to, the less likely they are to develop attention-deficit hyperactivity disorder (ADHD), a sweeping Metro Vancouver-wide study has found. 

The pathbreaking research, published in the journal Environment International, followed a cohort of roughly 37,000 children born in 2000 and 2001. 

Tracing a three-year exposure period, researchers from the University of British Columbia analyzed the combined impacts of satellite-measured green space, noise and concentrations of fine particulate matter smaller than 2.5 micrometres (PM 2.5) on the development of ADHD. Seven years after the exposure period, over 1,200 ADHD cases were diagnosed.

Noise was found to have no effect. But lower the amount of green space or increase the levels of air pollution, and the twin effects can heighten the risk of ADHD by up to 62 per cent, found researchers. The result: "children living in greener neighbourhoods with low air pollution had substantially lower risk of ADHD compared to those with higher air pollution and lower green space exposure," concluded the study.

“I was surprised that we saw this much of a difference,” said Michael Brauer, a co-author on the study and a researcher examining the built environment and human health at UBC’s School of Population and Public Health. 

“Given that there's not a lot of things about ADHD that we can change at a societal level, it is a pretty big effect.”

PM2.5 is the main constituent of wildfire smoke, something only expected to worsen in the coming decades. Outside of the fire season, Metro Vancouver says it's also produced through the burning of fossil fuels in everything from transportation, industry and agriculture. It has been considered a carcinogen since 2013. Across the world, the World Health Organization estimates almost 80 per cent of the deaths related to PM2.5 could be avoided if its guidelines were followed. 

Not all air pollutants were correlated with an increased risk of developing ADHD. Nitrogen dioxide — which together with PM 2.5 and ground-level ozone contributes to over 15,000 annual deaths across Canada and 1,900 in B.C. — was not found to be connected with the development of ADHD.

Brauer says the biggest two sources of air pollution driving the variation in Metro Vancouver were traffic and space heating, including wood-burning and natural gas fireplaces, and gas boilers. 

Closer to the coast and at higher elevations, pollution levels tended to be lower due to ocean breezes and the tendency of pollution to settle in low-lying areas. The worst-hit areas tended to be near major traffic arteries, along highways, major truck routes and the region’s ports.  

A neurodevelopmental disorder, ADHD is thought to affect five to 10 per cent of children and adolescents. Throughout a person's life, it can affect their academic performance and their ability to socialize and work.

As the researchers put it, ADHD has "considerable impacts on individual wellbeing, health care, and the economy." 

The study is part of a wider attempt to understand the environmental health hazards from air pollution and how green spaces can dampen their impacts. 

In October 2021, another Metro Vancouver-wide study from several of the same UBC researchers concluded living near green spaces improves a children's chances of hitting key developmental milestones, including emotional maturity, language skills and even general knowledge. 

Living near green spaces, found the 2021 study, could improve childhood development, partly by reducing the negative effects of air and noise pollution — both have been found to increase stress, sleep disturbances and central nervous system damage in children.

The latest round of research adds to a growing body of evidence of the benefits of green space on human health.

In other parts of the world, past research has found that access to green space can promote a huge range of positive health outcomes for all ages, from increased physical activity and social cohesion to reduced cardiovascular disease and dementia rates. Others have found similar benefits when people regularly expose themselves to bodies of water, known by some as "blue space."

Increased density of trees can also create a buffer for extreme heat and, in the winter, act as a thermal blanket that will reduce heating bills should a deep freeze set in. But how green spaces are distributed across the Metro area can reveal some huge inequalities.

Of the nearly 600 British Columbians who died from extreme temperatures during late June's heatwave, more were killed in low-income areas, where people lived alone and with little green space. On Vancouver's Downtown Eastside, Canada's poorest neighbourhood, hospitalizations tripled, with more people admitted to emergency rooms due to heat than anywhere else in the city.

Scientists know how trees protect us from heat. But how more access to green space makes people healthier over the long term is unclear. 

"Instead of saying green is good, we're providing more concrete pathways," Ingrid Jarvis told Glacier Media last fall.

At the time, Jarvis said the research shows that everyday "micro-contacts" with nature can positively affect a child's long-term physical and mental health. 

“This is one more thing,” added Brauer, referring to the group's latest study. “There’s not a lot known about factors that you can modify. So what we tend to do when kids are diagnosed with ADHD is put them on medication.”

“We could be raising healthier kids.”

Ultimately, their findings have big repercussions for how planners design neighbourhoods in a region expected to add another million people to its population by 2040.

In the past, the group of UBC researchers have sent findings to Metro Vancouver, where it was distributed to all 21 jurisdictions and various committees. 

Adblock test (Why?)


Could more nature and less air pollution prevent ADHD? - Powell River Peak
Read More

5 fentanyl poisonings, 1 death overnight in Guelph: public health - 915thebeat.com

Guelph’s public health unit announced Thursday morning that there were five drug poisonings in the city overnight caused by fentanyl, including one death.

In a series of tweets, the agency said all of the cases involved various colours of the deadly opioid including red, bright green and yellow.

Read more:

Guelph police BEAT unit investigation leads to weapons and drugs

But it added that any substance may pose a significant risk to drug users as what is being circulated may be stronger than usual.

Anyone using illicit drugs should never use alone, carry naloxone and take only one-third of a normal dose with any new purchase, officials said.

There is also a safe injection site at Guelph’s Community Health Centre in the city’s downtown core. It is open on weekdays from 9 a.m. to 5 p.m.

For those using alone, the National Overdose Response Service is a free anonymous service that can call drug users to check in on them. It can be reached at 1-888-688-6677.

© 2022 Global News, a division of Corus Entertainment Inc.

Adblock test (Why?)


5 fentanyl poisonings, 1 death overnight in Guelph: public health - 915thebeat.com
Read More

Reinfection with different subtypes of Omicron possible, study finds - EastMojo

London: Reinfection with the BA.2 subtype of the Omicron variant of coronavirus can occur shortly after initial infection with the BA.1 strain, according to a Danish study.

With the surge of Omicron subvariants BA.1 and BA.2, a large number of reinfections from earlier cases have been observed, the researchers said.

This has raised questions of whether BA.2 specifically can escape the natural immunity acquired shortly after a BA.1 infection, they said.

The researchers from Statens Serum Institut (SSI) in Denmark selected a subset of samples from over 1.8 million cases of infections in the period from November 22, 2021, until February 11, 2022.

The yet-to-be peer-reviewed study, posted on the preprint repository MedRxiv on Tuesday, identified a total of 187 reinfection cases.

The researchers found 67 cases in which the same individual had become infected twice at a 20-60-day interval, and where both infections were due to Omicron subtypes.

In 47 of the cases, the affected individual first became infected by BA.1 and then by BA.2, they said.

The majority of the infected were young and unvaccinated, and most experienced mild symptoms during their infections, according to the researchers.

The team noted that the difference between the severity during their first and second infection was negligible.

None of the infected individuals had become seriously ill, and none required admission to hospital, they said.

“The study shows that infection with two different Omicron subtypes is possible,” the authors of the study noted.

“This seems to occur relatively rarely in Denmark, and reinfections have mainly affected younger unvaccinated individuals, they added.

BTS announces four shows in Las Vegas following Grammy performance



Latest Stories

Adblock test (Why?)


Reinfection with different subtypes of Omicron possible, study finds - EastMojo
Read More

CDC Says Some People Can Wait Longer Between Covid Shots - BNN

(Bloomberg) -- Younger males and other healthy people under age 65 should consider waiting as long as eight weeks between their first and second doses of a messenger RNA Covid-19 vaccine, according to revised recommendations from the U.S. Centers for Disease Control and Prevention.

The new guidelines, posted to the agency’s website on Tuesday, were spurred by increasing evidence that a longer interval between doses in the so-called primary series could heighten the shots’ effectiveness and reduce the potential for rare heart-related side effects seen most frequently in adolescent boys and younger men.“These additional considerations followed a thorough evaluation of the latest safety and effectiveness data,” CDC spokesperson Kristen Nordlund said in an email. She said the new guidance is based on “evidence from hundreds of millions of Covid-19 vaccines that have already been safely administered in the United States.”Previously, the CDC recommended waiting three weeks between the first and second doses of the shot made by Pfizer Inc. and BioNTech SE, and four weeks between doses of Moderna Inc.’s Covid vaccine. The agency still recommends that schedule for people 65 and older, those with compromised immune systems, and others who need rapid protection from the coronavirus.

The update is meant to help health-care providers determine the optimal time interval for individual patients, Nordlund said. For younger males, extending the window between doses could help lower the risk of myocarditis and pericarditis, heart conditions that have been linked to mRNA vaccines. The overall risk of those conditions is small, the CDC said.

Some countries have already recommended waiting longer between vaccine doses. At the end of 2020, U.K. health officials extended the recommended interval between doses of AstraZeneca Plc's vaccine — which is based on a different technology — from a maximum of four weeks to 12 weeks. The main reason for the change was to stretch supplies, but a statement also noted data indicating that it would lengthen coverage and modestly increase efficacy. A study from the University of Oxford later found the delay was associated with an enhanced immune response.

 The 65% of Americans that have already had their two shots on the previous schedule remain well-protected, Nordlund said, especially if they get a booster dose.

©2022 Bloomberg L.P.

Adblock test (Why?)


CDC Says Some People Can Wait Longer Between Covid Shots - BNN
Read More

Wednesday, February 23, 2022

Never use drugs alone: Health Unit - Quinte News

The health unit serving Northumberland County is issuing advice to help reduce the risk of drug overdoses.

Basically the advice is – never use drugs while alone.

That potentially life-saving reminder is being shared by the Haliburton, Kawartha, Pine Ridge District Health Unit in the wake of separate overdose incidents over the past week in the City of Kawartha Lakes.

Substance and Harm Reduction Coordinator Catherine MacDonald says using substances alone can be dangerous as it may increase the risk of an overdose.

MacDonald says that person can call for emergency assistance or provide Naloxone if the need arises.”

The health unit statement is below:

Never use alone.

That simple, potentially life-saving reminder is being shared by the Haliburton, Kawartha, Pine Ridge District Health Unit in the wake of separate overdose incidents over the past week in the City of Kawartha Lakes. While these overdose incidents are unrelated, factors that may have contributed include a potent drug supply and using alone.

“While physical distancing and isolating are necessary to slow COVID-19, using substances alone can be dangerous as it may increase the risk of an overdose,” says Catherine MacDonald, a Registered Nurse and Substances and Harm Reduction Coordinator with the HKPR District Health Unit. “Using with a buddy can greatly reduce the risk, since someone else is there to call for emergency assistance or provide naloxone if the need arises.”

Naloxone is an emergency medicine that temporarily reverses the effects of an opioid overdose until the victim can get to hospital for treatment. The Health Unit and many local pharmacies provide free naloxone kits, and additional pickup points are also listed on the Ontario government website (www.ontario.ca/naloxone).

MacDonald says anyone who intervenes in an overdose situation is protected under the law. The Good Samaritan Act protects anyone trying to help in an emergency from possible legal repercussions, while the Good Samaritan Drug Overdose Act protects people on the scene of an overdose from being charged for possessing or using drugs.

If someone cannot or does not feel comfortable using drugs with someone else, there is another resource that can help. The National Overdose Response Service (NORS) virtual safe consumption – available at 1-888-668-NORS (6677) – lets people who use drugs connect with a NORS representative online or by phone. In an emergency, NORS can then be there for the person should a call for assistance be needed. “The National Overdose Response Service provides confidential, non-judgmental support whenever and wherever someone uses drugs,” MacDonald says. “It’s a great support service that has already saved many lives.”

If someone is using drugs, the Health Unit promotes these important safety tips:

  • Test a small amount of drug before you use. In many cases, overdoses can result from a contaminated or poisoned drug supply, of inconsistent or increased potency, causing more severe overdose reactions.
  • Never use alone. If you are alone, contact NORS for support, or use a buddy system and call a friend.
  • Ensure that emergency services can be contacted in the event of an overdose.
  • Avoid mixing your drugs.

Signs of an overdose include: very large or very small pupils, slow or no breathing, cold and clammy skin, blue or purple fingernails or lips, and snoring or gurgling sounds. Often in drug overdoses, it is also difficult to wake up the person.

“While these overdose incidents are unrelated, factors that may have contributed include a potent drug supply and using alone. While physical distancing and isolating are necessary to slow COVID-19, using substances alone can be dangerous as it may increase the risk of an overdose,” says Catherine MacDonald, a Registered Nurse and Substances and Harm Reduction Coordinator with the HKPR District Health Unit. “Using with a buddy can greatly reduce the risk, since someone else is there to call for emergency assistance or provide Naloxone if the need arises.”

Naloxone is an emergency medicine that temporarily reverses the effects of an opioid overdose until the victim can get to hospital for treatment. The Health Unit and many local pharmacies provide free Naloxone kits, and additional pickup points are also listed on the Ontario government website (www.ontario.ca/naloxone).

MacDonald says anyone who intervenes in an overdose situation is protected under the law. The Good Samaritan Act protects anyone trying to help in an emergency from possible legal repercussions, while the Good Samaritan Drug Overdose Act protects people on the scene of an overdose from being charged for possessing or using drugs.

If someone is using drugs, the Health Unit promotes these important safety tips:

  • Test a small amount of drug before you use. In many cases, overdoses can result from a contaminated or poisoned drug supply, of inconsistent or increased potency, causing more severe overdose reactions.
  • Never use alone. If you are alone, contact NORS for support, or use a buddy system and call a friend.
  • Ensure that emergency services can be contacted in the event of an overdose.
  • Avoid mixing your drugs.

Signs of an overdose include: very large or very small pupils, slow or no breathing, cold and clammy skin, blue or purple fingernails or lips, and snoring or gurgling sounds. Often in drug overdoses, it is also difficult to wake up the person.

Naloxone is an emergency medicine that temporarily reverses the effects of an opioid overdose… until the victim can get to hospital for treatment.

The Health Unit and many local pharmacies provide free Naloxone kits.

Adblock test (Why?)


Never use drugs alone: Health Unit - Quinte News
Read More

The Winnipeg Foundation Innovation Fund supports cutting-edge projects - UM Today

February 1, 2024 —  Three interdisciplinary teams from the Rady Faculty of Health Sciences have received $100,000 grants from The Winnipeg...